Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

OfficialStocktwitsUser Mar. 19 at 2:57 AM

$JSPR RSI: 36.36, MACD: -0.0481 Vol: 0.06, MA20: 1.33, MA50: 1.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JValis Mar. 12 at 12:41 AM

$JSPR

0 · Reply

BillionerOfKing Mar. 10 at 9:44 PM

$JSPR Current Stock Price: $1.38 Contracts to trade: $1.5 JSPR Mar 20 2026 Call Entry: $0.27 Exit: $0.47 ROI: 75% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CoachHendo Mar. 6 at 5:58 PM

$JSPR Bullish!

0 · Reply

MikiTrader Mar. 5 at 11:41 PM

$JSPR Could be a first in class mechanism, but not fully certain yet. If Phase 2 succeeds, a $500M to $800M market cap seems possible based on typical biotech revaluation after strong mid stage data. Still meaningful risk though. I estimate around a 30% chance of failure.

1 · Reply

MikiTrader Mar. 5 at 1:30 AM

$JSPR I read it. Not much new, but the data looks legit. Now I am just wondering when this finally makes a bigger move. If they wanted to, they could make a ton of money here, so please do not go the wrong way.

1 · Reply

Parobull Mar. 4 at 11:48 PM

Watch ticker CXAI is one of those setups where the balance sheet vs price disconnect stands out. Strong cash reserves, long runway, and already proven it can gap overnight. With penny stock momentum rotating again, these kinds of charts can wake up quickly. $JSPR $ELBM $DTIL $NVVE

0 · Reply

Bullshyte Mar. 4 at 8:25 PM

$JSPR Extremely

1 · Reply

Mario19860 Mar. 2 at 4:43 PM

$JSPR today news?

0 · Reply

MikiTrader Feb. 28 at 11:00 PM

$JSPR It appears the company has reached a point where it is significantly discounted due to a series of events. The underlying value still seems to remain, and forcing investors to abandon everything because of an operational error does not appear desirable, especially when viewed in light of past precedents.

0 · Reply

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jan 8, 2026, 11:44 AM EST - 2 months ago

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jan 8, 2026, 7:00 AM EST - 2 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jan 7, 2026, 4:30 PM EST - 2 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Dec 2, 2025, 5:53 PM EST - 3 months ago

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript

Dec 2, 2025, 7:00 AM EST - 3 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 3 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 22, 2025, 11:49 PM EST - 4 months ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

Nov 17, 2025, 12:13 PM EST - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 4 months ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 8:00 AM EST - 4 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 9:52 AM EST - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 4, 2025, 8:00 AM EST - 4 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Oct 10, 2025, 8:05 PM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 6 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 6 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 6 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 8 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 9 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 9 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 9 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 10 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 11 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 1 year ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

OfficialStocktwitsUser Mar. 19 at 2:57 AM

0 · Reply

JValis Mar. 12 at 12:41 AM

$JSPR

0 · Reply

BillionerOfKing Mar. 10 at 9:44 PM

0 · Reply

CoachHendo Mar. 6 at 5:58 PM

$JSPR Bullish!

0 · Reply

MikiTrader Mar. 5 at 11:41 PM

1 · Reply

MikiTrader Mar. 5 at 1:30 AM

1 · Reply

Parobull Mar. 4 at 11:48 PM

0 · Reply

Bullshyte Mar. 4 at 8:25 PM

$JSPR Extremely

1 · Reply

Mario19860 Mar. 2 at 4:43 PM

$JSPR today news?

0 · Reply

MikiTrader Feb. 28 at 11:00 PM

0 · Reply

kellymone2 Feb. 18 at 10:06 PM

$JSPR climbing

0 · Reply

Mario19860 Feb. 17 at 4:22 PM

$JSPR any news?

1 · Reply

VolatilityTermStructure Feb. 17 at 12:51 PM

$JSPR Pre-revenue biotech; early-stage.

0 · Reply

Biotech41 Feb. 13 at 9:05 PM

$JSPR Another red day... cannot get a break

0 · Reply

Biotech41 Feb. 12 at 9:01 PM

$JSPR Not a single green day :/

2 · Reply

OfficialStocktwitsUser Feb. 12 at 11:43 AM

$JSPR RSI: 27.40, MACD: -0.1072 Vol: 0.12, MA20: 1.47, MA50: 1.65 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply